Evidence map›Paper›PMID 24379924›Full record

ReviewWorld journal of diabetes2013

Diabetic macular edema: New promising therapies.

Hanan N Al Shamsi, Jluwi S Masaud, Nicola G Ghazi

2 registry-linked trialsAbstract readReview
In one paragraph

Review in World journal of diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328118 phase2 / phase3unknown statusnot on this mapstarted 2015, after this paper: background citation

25-Gauge Vitrectomy Combine With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in Chinese Patients

TypeinterventionalSponsorJUNYAN ZHANGRan2015 to 2017Enrolled120ConditionsProliferative Diabetic RetinopathyArmsRanibizumab, Triamcinolone Acetonide
NCT02447185 phase3unknown statusnot on this mapstarted 2015, after this paper: background citation

25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China: a Randomized, Single Blind Trial

TypeinterventionalSponsorJUNYAN ZHANGRan2015 to 2021Enrolled200ConditionsProliferative Diabetic RetinopathyArmsRanibizumab, Triamcinolone Acetonide
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Diabetic Retinopathy and Diabetic Macular Edema.Developments in ophthalmology · 2016
    Review
  7. Article
  8. Review
  9. Advances in diabetic retinopathy.Indian journal of endocrinology and metabolism · 2014
    Review
  10. Review
  11. Diabetic macular edema: Current management 2013.World journal of diabetes · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hanan N Al ShamsiHanan N Al Shamsi, Jluwi S Masaud, Nicola G Ghazi, The Vitroretinal Division, King Khaled Eye Specialist Hospital, Riyadh 11462, Saudi Arabia.
Jluwi S MasaudHanan N Al Shamsi, Jluwi S Masaud, Nicola G Ghazi, The Vitroretinal Division, King Khaled Eye Specialist Hospital, Riyadh 11462, Saudi Arabia.
Nicola G GhaziHanan N Al Shamsi, Jluwi S Masaud, Nicola G Ghazi, The Vitroretinal Division, King Khaled Eye Specialist Hospital, Riyadh 11462, Saudi Arabia.
King Khaled Eye Specialist Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of diabetic macular edema is rapidly evolving. The era of laser therapy is being quickly replaced by an era of pharmacotherapy. Several pharmacotherapies have been recently developed for the treatment of retinal vascular diseases such as diabetic macular edema. Several intravitreal injections or sustained delivery devices have undergone phase 3 testing while others are currently being evaluated. The results of clinical trials have shown the superiority of some of these agents to laser therapy. However, with the availability of several of these newer agents, it may be difficult to individualize treatment options especially those patients respond differently to various therapies. As such, more effort is still needed in order to determine the best treatment regimen for a given patient. In this article, we briefly summarize the major new therapeutic additions for the treatment of diabetic macular edema and allude to some future promising therapies.

Indexed as

Diabetic macular edemaDiabetic retinopathyIntravitreal injectionLaser photocoagulationPharmacotherapySustained release drug delivery devicesVitrectomy

Identifiers

PMID24379924
PMCPMC3874493
OpenAlexW2125593143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.